A phase 2 study of Velcade [bortezomib] in subjects with relapsed or refractory follicular B-cell lymphoma.

Trial Profile

A phase 2 study of Velcade [bortezomib] in subjects with relapsed or refractory follicular B-cell lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Dec 2012

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Feb 2009 Additional lead trial centre and lead investigator identified as reported by ClinicalTrials.gov, last updated 9 Feb 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top